Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-11-27 9:24 pm Unchanged |
2023-11-20 | 13D | RVL Pharmaceuticals plc RVLPQ |
Athyrium Opportunities IV Acquisition 2 LP | 14,600,444 13.100% |
0 (Unchanged) |
Filing History |
| 2023-11-01 4:27 pm Sale |
2023-10-18 | 13D | RVL Pharmaceuticals plc RVLPQ |
Altchem Ltd | 1,182,243 1.100% |
-22,485,297 (-95.00%) |
Filing History |
| 2023-10-13 5:28 pm Unchanged |
2023-10-12 | 13D | RVL Pharmaceuticals plc RVLPQ |
Athyrium Opportunities IV Acquisition 2 LP | 14,600,444 13.100% |
0 (Unchanged) |
Filing History |
| 2023-09-05 07:45 am Unchanged |
2023-09-05 | 13D | RVL Pharmaceuticals plc RVLPQ |
Athyrium Opportunities IV Acquisition 2 LP | 14,600,444 13.100% |
0 (Unchanged) |
Filing History |
| 2023-08-17 5:06 pm Sale |
2023-08-15 | 13D | RVL Pharmaceuticals plc RVLPQ |
Avista Healthcare Partners GP Ltd. | 0 0.000% |
-23,730,864 (Position Closed) |
Filing History |
| 2023-01-30 5:23 pm Purchase |
2023-01-27 | 13D | RVL Pharmaceuticals plc RVLPQ |
Avista Healthcare Partners GP Ltd. | 23,730,864 23.900% |
23,730,864 (New Position) |
Filing History |
| 2022-08-11 3:53 pm Purchase |
2022-08-08 | 13G | RVL Pharmaceuticals plc RVLPQ |
Athyrium Opportunities IV Acquisition 2 LP | 14,600,444 14.750% |
6,262,242 (+75.10%) |
Filing History |
| 2022-08-09 5:20 pm Purchase |
2022-08-08 | 13D | RVL Pharmaceuticals plc RVLPQ |
Avista Capital Partners III GP L.P. | 23,730,864 24.000% |
8,000,000 (+50.86%) |
Filing History |
| 2021-11-03 4:30 pm Unchanged |
2021-10-12 | 13D | RVL Pharmaceuticals plc RVLPQ |
Altchem Ltd | 23,667,540 28.400% |
0 (Unchanged) |
Filing History |
| 2021-10-22 4:27 pm Purchase |
2021-10-12 | 13G | RVL Pharmaceuticals plc RVLPQ |
Athyrium Opportunities IV Acquisition 2 LP | 8,338,202 9.990% |
8,338,202 (New Position) |
Filing History |
| 2021-10-14 4:10 pm Unchanged |
2021-10-12 | 13D | RVL Pharmaceuticals plc RVLPQ |
Avista Capital Partners III GP L.P. | 15,730,864 18.900% |
0 (Unchanged) |
Filing History |
| 2021-04-29 4:49 pm Sale |
2021-04-01 | 13G | RVL Pharmaceuticals plc RVLPQ |
Orbit Co-Invest I LLC | 0 0.000% |
-4,936,926 (Position Closed) |
Filing History |
| 2020-11-25 7:01 pm Purchase |
2020-11-20 | 13G | RVL Pharmaceuticals plc RVLPQ |
Orbit Co-Invest I LLC | 4,936,926 7.900% |
4,936,926 (New Position) |
Filing History |
| 2020-11-23 4:53 pm Unchanged |
2020-11-20 | 13D | RVL Pharmaceuticals plc RVLPQ |
Avista Capital Partners III GP L.P. | 15,730,864 25.200% |
0 (Unchanged) |
Filing History |